Improving the lives of people suffering from mental illness and substance use disorders

Developing improved pharmaceuticals based on innovative drug delivery technologies

Providing evidence-based digital therapies to improve treatment outcomes

What we do

Pharmaceuticals

Pharmaceuticals

Commercializing and developing pharmaceuticals addressing large unmet needs

Digital Therapeutics

Digital Therapeutics

Product portfolio of scientifically proven digital therapies

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

We Care

Shedding light on lives affected by addiction and the road to recovery

Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.

Key News

JUNE 14, 2021
Orexo´s partner Gesynta Pharma reports progresses with the OX-MPI study

JUNE 2, 2021
ZUBSOLV's patent portfolio is strengthened with two new patents

APRIL 29, 2021
Q1 2021 Interim Report

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

Orexo Social

24 June 2021

According to new data presented by @CDCgov, which applies to the period Dec. 1, 2019 – Nov. 30, 2020, the number of… https://t.co/m12zkqUifW

21 June 2021

According to new data from @CDCgov overdose deaths continues to surge. In parallel multiple businesses confront a w… https://t.co/yuiYyEnKDS

18 June 2021

WOMEN IN WELLNESS series: Thanks to @ChayaWeiner @AuthorityMag for a great interview with our colleague Mikaela Odl… https://t.co/8AcHswmY1K

Financial Snapshot

Group net revenues

621 MSEK

LTM1

Group EBITDA

-44 MSEK

LTM1

US Pharma segment EBIT

322 MSEK

LTM1

Cash position

726 MSEK

Q1 2021

1 Last Twelve Months, Q220-Q121, for more information about financial development Link